Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer
Novartis announced March 15 that its investigational compound LDK378 has received Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small […]